Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Levetiracetam (also known as UCB-L059, SIB-S1) is a potent and selective M2 muscarinic acetylcholine receptors (mAChR) inhibitor and an anticonvulsant medication used to treat epilepsy. Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons.
ln Vitro |
Levetiracetam inhibits the activity of O6-methylguanine-DNA-methyltransferase (MGMT) by increasing HDAC transcription and enlisting corepressor complexes on the promoter [1]. Glioblastoma multiforme stem-like cells (GSC) are made more sensitive to temozolomide (250 μM) treatment by levetiracetam (40 μg/mL) [1]. Levetiracetam (40 μg/mL) treatment of GCSCs results in down-regulated MGMT expression[1].
|
---|---|
ln Vivo |
Levetiracetam (10, 25, or 50 mg/kg) suppresses EEG and behavioral seizure activity in neonates experiencing hypoxia [2].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: GCSC neurospheres Tested Concentrations: 40 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: Slight antitumor effect exerted by the treatment with Temozolomide (250 µM) or Levetiracetam (40 μg/mL) alone was strongly enhanced when Temozolomide and Levetiracetam were added in combination. Western Blot Analysis[1] Cell Types: Glioblastoma multiforme stem-like cells (GSCs) Tested Concentrations: 40 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: A high level of MGMT expression in untreated GCSCs; this expression was slightly diminished after treatment with Temozolomide (250 µM) and Levetiracetam singularly but it was dramatically diminished after the combined treatment with Temozolomide and Levetiracetam. |
Animal Protocol |
Animal/Disease Models: Male Long-Evans rats[2]
Doses: 10, 25, or 50 mg/kg Route of Administration: intraperitoneal (ip)injection 60 min before hypoxia. Experimental Results: Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25 mg/ kg and at 50 mg/kg. Anticonvulsant activity was maximal at 50 mg/kg, at which HSs were decreased by 63.6%. |
References |
[1]. Bianca Maria Scicchitano, et al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018 Sep 10;18:136.
[2]. Delia M Talos, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2013 Jan;73(1):24-30. |
Molecular Formula |
C8H14N2O2
|
---|---|
Molecular Weight |
170.21
|
CAS # |
102767-28-2
|
Related CAS # |
Etiracetam;33996-58-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(N)[C@H](CC)N1C(CCC1)=O
|
InChi Key |
HPHUVLMMVZITSG-LURJTMIESA-N
|
InChi Code |
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
|
Chemical Name |
(S)-2-(2-oxopyrrolidin-1-yl)butanamide
|
Synonyms |
Levetiracetam, UCBL059, UCB L059, UCB-L059, SIB S1, SIBS1, SIB-S1, Keppra, Etiracetam, UCB6474, UCB-6474,
UCB 6474,
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: Saline: 30 mg/mL Solubility in Formulation 5: 100 mg/mL (587.51 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.8751 mL | 29.3755 mL | 58.7510 mL | |
5 mM | 1.1750 mL | 5.8751 mL | 11.7502 mL | |
10 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06224530 | Not yet recruiting | Drug: Levetiracetam Drug: Placebo |
Psychosis | King's College London | February 2024 | Not Applicable |
NCT04004702 | Not yet recruiting | Drug: Levetiracetam | Alzheimer Disease | Walter Reed National Military Medical Center |
January 2020 | Phase 2 |
NCT04317807 | Recruiting | Drug: Levetiracetam Pill Other: Placebo |
Early Psychosis | NYU Langone Health | August 27, 2020 | Phase 2 |
NCT06067412 | Completed | Drug: Levetiracetam Drug: Phenytoin |
Status Epilepticus | Shaheed Zulfiqar Ali Bhutto Medical University |
August 1, 2022 | Not Applicable |